Custom Search

Sunday, April 19, 2020

New Drug Remdesivir found working against COVID19 clinical trial conducted on monkeys

Drug Remdesivir was found to protect rhesus macaques (monkeys).
Two group of 6 monkeys were formed and all 12 monkeys were infected with sars-cov-2 virus (ncov19) found that 6 monkeys which was given Remdesivir were protected from damaging effect of sars-cov-2 virus on lungs. While other group of monkeys which did not receive drug was reported to have difficulty in breathing and developed the COVID19 disease.

Drug Remdesivir suppose to be tested in higher number of multi center clinical trails involving COVID19 patients, drug Remdesivir designed to work against EBOLA virus, and it has shown good outcomes against EBOLA virus was tested in monkeys in 2015.

Drug Remdesivir dveloped by Gilead sciences, it is a product which get converted in body in to active adinosine nucleotide analog drug and inhibit formation of viral RNA thereby hampering the multiplication of virus.





No comments:

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner

Join the list of our readers from Universities ,Research and
Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2020 all rights reserve www.pharmacistspharmajournal.org